PO14
FACTORS EFFECTING SURVIVAL IN PATIENTS WITH GLIOBLASTOMA MULTIFORME Free

INTRODUCTION: Glioblastoma multiforme (GBM) is a common intracranial tumour and carries a poor prognosis.The aim of this study was to identify prognostic factors of survival for patients diagnosed with GBM in the West of Scotland. METHOD: A retrospective study was carried out on all patients diagnosed with GBM in Glasgow between 2010-2012. Survival was defined as the number of days from the diagnostic surgery to death. Data was collected on age, WHO performance status, surgical resection, MGMT and IDH status, Temozolomide, radical and palliative radiotherapy, and medications at the time of diagnosis. Statistical analysis was carried out using SPSS. The Log rank test was used to generate p values and Kaplan-Meier graphs to display the data. RESULTS: The total sample size was 226. The median survival for patients aged <50 was 396 days compared with 158 for those older than 69 (p<0.001). Patients with a WHO performance status 0 survived for a median of 549 days versus 83 in those with >2 (p < 0.001). In patients who underwent radical radiotherapy, methylated MGMT was associated with a median survival of 747 days compared with 357 in unmethylated (p < 0.001). In patients who underwent palliative radiotherapy, methylation status was not associated with prolonged survival (p = 0.3).Within the radical radiotherapy subgroup (n = 110), there were 6 patients who were taking Metformin at the time of diagnosis. The median survival of these patients was 582 days compared with 453 in those not taking Metformin. Simvastatin usage did not correlate with survival. CONCLUSION: Age, WHO performance status, surgical resection and MGMT methylation in patients receiving radical radiotherapy are prognostic indicators of survival in GBM.